
KLOW 80mg (Pen)
80 mg
$349.99 CAD

GIP,GLP-1 and glucagon receptor triple agonist · Research reagent
GLP-3 is a nickname for retatrutide. It targets three receptors, GLP-1, GIP and glucagon, and is being studied in clinical trials on metabolism and body weight.
$499.99 CAD
Vial discount: 5% off at 3, 10% at 5, 20% at 10 eligible single vials, any mix. Applied automatically in the cart.
Interac e-Transfer
$9.99 shipping, free from $250 · Ships from Canada · Canada only
Shipping and returns: Ships next business day from Canada · $9.99 shipping, free from $250 · Arrives right or we make it right
For research use only. Not for human consumption.
Lab report available on request.
GLP-3 30mg Pen, also published as Retatrutide and LY3437943, is catalogued here as: GIP, GLP-1 and glucagon receptor triple agonist. GLP-3 is a nickname for retatrutide, studied in adults for metabolic and body-weight outcomes. It targets GLP-1, GIP and glucagon receptors: three targets, not three established benefits. GLP-3 is the informal catalogue name used here for retatrutide, a multi-receptor peptide agonist studied in metabolic research. The “3” refers informally to three named targets: GLP-1, GIP and glucagon receptors. GLP-3 is not itself a scientific receptor name, and receptor activity and clinical outcomes are separate questions. GLP-3 is a nickname for retatrutide. It targets three receptors, GLP-1, GIP and glucagon, and is being studied in clinical trials on metabolism and body weight.
Metabolic research of this kind uses randomized, placebo-controlled trials with defined populations and durations, measuring body-weight endpoints together with adverse events such as gastrointestinal symptoms and heart-rate changes.
A 2023 phase 2 randomized, placebo-controlled trial in 338 adults over 48 weeks reported lower body-weight outcomes in the study arms, along with gastrointestinal adverse events and heart-rate increases.
Human trial literature: Jastreboff et al. (NEJM, 2023) randomized 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week phase 2 trial. Receptor activity concerns metabolic signalling; measured weight change is a separate endpoint, not proof of an appetite mechanism or a BLOOM product effect.
Bloom Labs lists GLP-3 30mg Pen as a pen in 30 mg. Prices are shown in Canadian dollars, and orders ship from Canada by tracked Canadian service.
A lab report for GLP-3 30mg Pen is available on request. Bloom Labs does not display a report until it is matched to the exact compound and strength.
Shipped lyophilized (freeze-dried) and stable at room temperature in transit. Store sealed vials in the fridge or freezer on arrival. Once reconstituted, refrigerate. Anything not right? Our guarantee covers it.

80 mg
$349.99 CAD

20 mg
$299.99 CAD

40 mg
$299.99 CAD